Apexigen, Inc.

Apexigen, Inc. is a clinical-stage biopharmaceutical company focused on oncology that completed its business combination with Brookline Capital Acquisition Corp (Nasdaq: BCAC), a blank-check company sponsored by Brookline Capital Markets, in July 2022. Brookline Capital Acquisition Corp conducted its initial public offering in 2021, targeting the life sciences and biotechnology sector. Following the de-SPAC transaction, the combined entity began trading on Nasdaq under the ticker APGN. The 10-Q filing dated August 18, 2022, accession number 0001193125-22-224171, represents Apexigen's first quarterly disclosure as a newly public company post-merger. Sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics across the SPAC universe.